Generic drug industry Waxman/Hatch agenda to shape debate urged by Rep. Waxman.
This article was originally published in The Tan Sheet
Executive Summary
GENERIC INDUSTRY SHOULD DEVELOP WAXMAN/HATCH AGENDA to address concerns regarding the drug patent law, Rep. Henry Waxman (D-Calif.) suggested at the National Association of Pharmaceutical Manufacturers mid-year meeting in Washington, D.C. June 23. "Oftentimes, the legislative process is responding to those who are coming in with demands," Waxman pointed out. "If you think that you need to press for more changes, you ought to do it," he advised. "The demands that are made may not get granted, but it certainly puts them on the agenda, so I leave it to you to figure out what you want on the agenda."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning